Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of allergic conjunctivitis to ragweed for at least one year~* Positive skin prick test to ragweed pollen within 12 months prior to visit 1~* BCVA of at leat 20/400~Exclusion Criteria:~* Structural lid abnormalities (ectropion, entropion)~* Active lid disease ( ie moderate or severe blepharitis, meibomianitis) that requires medical treatment~* Presence of follicular conjunctivitis, anterior uveitis or preauricular lymphadenopathy~* History of ophthalmic abnormality, including a history of dry eye~* Perennial allergic rhinoconjunctivitis having significant allergy to animal dander that cannot be avoided during the study period~* History of chronic bacterial or viral ocular infection, such as herpes keratitis, and/or presence of active bacterial or viral ocular infection~* presence of mucous discharge, excess lacrimation or burning as a symptoms of ocular disease~* Currently on any chronic ocular topical medications~* Use of topical or systemic ocular medications during the study period~* History of complications, adverse events, trauma or disease in the nasolacrimal area~* History of symptomatic epiphoria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lower Puncta Delivery (Type: EXPERIMENTAL): None
- Double Puncta Delivery (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).